

Annex L: Products that have potentially low profit margins, as indicated by the WHO Prequalification program¹


WHO/PQT	Guidance Document 13 September 2017
---------	--

**WHO Prequalification Fees
ANNEX**

PRODUCTS THAT HAVE BEEN INDICATED TO POTENTIALLY HAVE LOW PROFIT MARGINS

A. SPECIFIC PRODUCTS

1. Amikacin 500mg
2. Amikacin 500mg/2mL
3. Amoxicillin/Clavulanate 250/125mg
4. Amoxicillin/Clavulanate 500/125mg
5. Amoxicillin/Clavulanate 875/125mg
6. Capreomycin 0.5gm
7. Capreomycin 0.75gm
8. Capreomycin 1gm
9. Clofazamine 100mg
10. Clofazamine 50mg
11. Cycloserine 125mg
12. Ethambutol 100mg
13. Ethambutol 400mg
14. Ethionamide 125mg
15. Ethionamide 250mg
16. Imipenem/Cilastation 500/500mg
17. Isoniazid 100mg
18. Isoniazid 300mg
19. Kanamycin 0.5gm
20. Levofloxacin 100mg
21. Levofloxacin 250mg
22. Levofloxacin 500mg
23. Levofloxacin 750mg
24. Linezolid 150mg
25. Linezolid 600mg
26. Moxifloxacin 100mg
27. Moxifloxacin 400mg
28. Oseltamivir Phosphate Capsules 30mg
29. Oseltamivir Phosphate Capsules 45mg
30. PAS Products
31. Prothionamide 250mg
32. Pyrazinamide 150mg
33. Pyrazinamide 400mg
34. Pyrazinamide 500mg

WHO Prequalification Fees 1 WHO PREQUALIFICATION TEAM  World Health Organization

¹ https://extranet.who.int/prequal/sites/default/files/documents/PQ_Fees_Annex_092017.pdf

35. Rifabutin 150mg
36. Rifampicin 150mg
37. Rifampicin 300mg
38. Rifampicin/Isoniazid 150/150mg
39. Rifampicin/Isoniazid 75/50mg
40. Rifampicin/Isoniazid/Ethambutol 150/75/275mg
41. Rifampicin/Isoniazid/Pyrazinamide 75/50/150mg
42. Rifapentine 150mg
43. Rifapentine/Isoniazid 150/150mg
44. Rifapentine/Isoniazid 300/300mg
45. Terizidone 250mg
46. 4-in-1 HIV/TB prophylaxis

B. GENERAL PRODUCT CATEGORIES

1. Seasonal influenza vaccines.
2. Pandemic influenza vaccines
3. Emergency vaccines (e.g. ebola, polio) required in the context of a Public Health Emergency of International Concern (PHEIC).
4. Pharmaceutical products formulated specifically for Paediatrics.